



February 7, 2025

Dockets Management Staff (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane, Rm 1061  
Rockville, MD 20852

Submitted via <http://www.regulations.gov>

**Re: Docket No. FDA-2022-D-0465**

Dear Dockets Manager:

The Eye Bank Association of America (EBAA) appreciates the opportunity to provide comments in response to the Food and Drug Administration's draft guidance entitled "*Recommendations to Reduce the Risk of Transmission of Hepatitis B Virus (HBV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)*" [Docket No. FDA-2022-D-0466].

The EBAA is the world's oldest transplantation association, established in 1961 by the American Academy of Ophthalmology (AAO) and is the nationally recognized accrediting and standards setting body for eye banks.

The association strives to ensure the superior quality of banked human eye tissue through the adoption and implementation of stringent medical standards, which are scientifically based, and specific to ocular tissue. The association is committed to "the restoration of sight worldwide," and works toward this vision by developing and delivering standards, accreditation, and educational programs that optimize patient and donor care and safety.

EBAA eye banks are non-profit organizations that recover, medically evaluate, process, and distribute ocular tissue for transplant, research, and education. In 2023, U.S. EBAA eye banks provided tissue for 86,986 sight-restoring corneal transplant surgeries.<sup>1</sup>

The EBAA appreciates this opportunity to provide public comments on proposed Center for Biologics Evaluation and Research (CBER) regulatory requirements. On behalf of our member banks, we would like to offer these general comments for consideration.

#### **COMMENT 1 – Support for draft guidance recommendations**

EBAA commends the FDA for their extensive work to support this landmark policy change resulting in new, evidence-based recommendations for donor eligibility criteria while maintaining appropriate safeguards to protect patients receiving tissue transplants.

We applaud the elimination of the donor screening questions specific to men who have sex with men (MSM) and women who have sex with MSM and, instead recommending that establishments assess HCT/P donor eligibility using the same individual risk-based questions for every donor regardless of sex or gender.

The risk for HBV (and HCV and HIV) is assessed through sexual practices and not through sexual orientation, so that individuals who report having a new sexual partner and anal sex in the past three months or multiple sexual partners and anal sex in the three last months would be deferred. Similarly, physical evidence of perianal lesions in all donors (male and female) would be considered high-risk behavior for HIV.

The uniform use of HBV NAT testing for all HCT/P donors since 2016 will detect HBV RNA 2 to 5 weeks after infection and up to 40 days (mean 6 to 15 days) before HBsAg. This supports the reduction of certain time-based deferrals for HBV risk factors and conditions to a 3-month deferral period.

**COMMENT 2 –Request for clarification as to the definition of a “new sexual partner”.**

Our members are requesting that FDA provide a definition of “new partner.”

The guidance includes the following examples which would be considered having sex with a new partner: having sex with someone for the first time; or having had sex with someone in a relationship that ended in the past and having sex again with that person in the last 3 months.

This could be problematic at the operational level. For example, would a military spouse deployed for a year be considered a “new partner” upon return?

**COMMENT 3 - Clarification of the risk assessment timeframe for the secondary sexual partner**

Section IV. Recommendations, page 9:

**A. Screening a Donor for Risk Factors and Conditions of HBV Infection**

The following conditions or behaviors should be considered risk factors for HBV:

5. Persons who have had sexual contact in the preceding 3 months with any individual who has exchanged sex for money, drugs, or other payment. If there is any uncertainty about when their sexual partner exchanged sex for money, drugs or other payment, the person is ineligible for 3 months.
6. Persons who have had sexual contact in the preceding 3 months with any individual who has engaged in non-prescription injection drug use. If there is any uncertainty about when their sexual partner engaged in non-prescription injection drug use, the person is ineligible for 3 months.



The eligibility assessment should consider the timeframe for the sexual partner's injection drug use or payment for sex to be consistent with all other time-bound donor screening questions.

Without a timebound recommendation for the secondary sexual contact, the donor would be determined to be ineligible for sexual contact with anyone who has EVER "exchanged sex for money, drugs or other payment" and anyone who has EVER "engaged in non-prescription drug use." This results in an inconsistent eligibility determination of certain donors based on sexual contact with individuals who are themselves eligible to donate.

We suggest an evidence-based approach to evaluate HBV risk related to sexual contact, consistently applying the 3-month deferral period. For example:

- Persons who have had sexual contact in the preceding 3 months with any individual who has, in the past 3 months, exchanged sex for money, drugs or other payment...
- Persons who have had sexual contact in the preceding 3 months with any individual who has, in the past 3 months, engaged in non-prescription injection drug use...

#### **COMMENT 4 – Consider discontinuation of HBsAg testing requirement.**



Recommended donor screening tests for all HCT/P donors In section D, page 12 include:

1. FDA-licensed donor screening test for hepatitis B surface antigen (HBsAg); and
2. FDA-licensed donor screening test for total antibody to hepatitis B core antigen (total anti-HBc means IgG and IgM); and
3. FDA-licensed donor screening Nucleic Acid Test for HBV (HBV NAT); or a combination or multiplex NAT that includes HBV.

Any HCT/P donor whose specimen tests positive (or reactive) using any of the assays (i.e., HBsAg, total anti-HBc (IgG and IgM), or HBV NAT) is considered ineligible.

During our April 18, 2024, Executive Liaison meeting with FDA, we shared our concerns with an alarming increase in donors with positive HBsAg test results, which accounted for 3,554 (11.3%) of tissues not released for transplant in 2023. This was a 281% increase over the 2020 baseline rate, while HBV NAT results showed no increase and only accounted for 607 tissues.

While we are still collecting and analyzing data for 2024, preliminary data reveals 2,933 tissues with HBsAg positive results compared with 673 HBV NAT positive tissues. The small drop in positive HBsAg testing was due to eye banks switching from problematic testing platforms or reverting to manual HBsAg testing.





HBV DNA is detected earlier in the window period and remains positive longer than HBsAg, so requiring the latter is redundant and appears problematic in cadaveric donors. Anti-HBc will continue to be necessary to detect occult infection.

#### **COMMENT 5 – Request for an extended implementation period**

EBAA requests an extended implementation period of at least six months. This period should allow facilities to focus on successful implementation of changes to highly complex systems which must be updated, tested, and validated for performance. These include changes to the establishment’s computer system, Donor Risk Assessment Interview (DRAI) questionnaires, flowcharts, policies and procedures, and extensive staff training and education.

#### **Conclusion**

The EBAA thanks the FDA for this opportunity to comment on existing CBER regulations. The Association appreciates the FDA’s efforts to help ensure the safety of human tissues for transplant and prevent the transmission of communicable disease by HCT/Ps.

We are committed to working with the Agency to ensure that its approach is evidence-based, risk-based, and does not inadvertently interfere with patients’ access to cornea and tissue transplants.

Sincerely,

A handwritten signature in black ink, appearing to read "Kevin P. Corcoran".

Kevin P. Corcoran, CAE  
President & CEO

#### **References**

1. Eye Bank Association of America (2024). “[2023 Eye Banking Statistical Report](#)”.
2. [https://www.researchgate.net/figure/Course-of-serum-markers-in-acute-resolving-hepatitis-B-virus-infection-The-curves-in\\_fig1\\_362148887](https://www.researchgate.net/figure/Course-of-serum-markers-in-acute-resolving-hepatitis-B-virus-infection-The-curves-in_fig1_362148887)